Compare · RMD vs TNDM
RMD vs TNDM
Side-by-side comparison of ResMed Inc. (RMD) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.40B, about 21.5x TNDM ($1.55B).
- Over the past year, RMD is down 19.0% and TNDM is up 83.9% - TNDM leads by 102.9 points.
- TNDM has been more active in the news (11 items in the past 4 weeks vs 8 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- ResMed Inc.
- Tandem Diabetes Care Inc.
- Price
- $231.49+1.22%
- $22.29-1.33%
- Market cap
- $33.40B
- $1.55B
- 1M return
- +20.68%
- +32.05%
- 1Y return
- -18.98%
- +83.91%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest RMD
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
- ResMed downgraded by RBC Capital Mkts with a new price target
Latest TNDM
- William Blair initiated coverage on Tandem Diabetes Care
- EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh converted options into 4,120 shares and covered exercise/tax liability with 1,479 shares, increasing direct ownership by 5% to 52,040 units (SEC Form 4) to satisfy withholding tax
- PRESIDENT & CEO Sheridan John F converted options into 15,916 shares and covered exercise/tax liability with 8,099 shares, increasing direct ownership by 5% to 160,260 units (SEC Form 4) (for withholding tax)
- EVP, Chief Strategy Officer Gasser Elizabeth Anne converted options into 3,014 shares and covered exercise/tax liability with 1,618 shares (SEC Form 4) to satisfy withholding tax
- EVP & Chief Admin. Officer Morrison Susan converted options into 2,827 shares and covered exercise/tax liability with 809 shares, increasing direct ownership by 4% to 52,788 units (SEC Form 4) (tax withholding)
- EVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 1,010 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 2% to 30,290 units (SEC Form 4) (for withholding tax)
- EVP & Chief Technology Officer Carpenter Rick converted options into 2,507 shares and covered exercise/tax liability with 1,277 shares, increasing direct ownership by 4% to 32,148 units (SEC Form 4) (for tax liability)
- EVP & Chief Legal Officer Hansen Shannon Marie converted options into 3,014 shares and covered exercise/tax liability with 1,535 shares, increasing direct ownership by 5% to 31,650 units (SEC Form 4) to cover taxes
- SEC Form 10-Q filed by Tandem Diabetes Care Inc.
- Tandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits